Tel Aviv Stock Exchange Ltd. · TASE:TASE
Tel Aviv Stock Exchange — Clal Biotechnology Industries — Investor Presentation (November 2020)
19 slides from Tel Aviv Stock Exchange's investor presentation, November 2020
Slide 1: Corporate Presentation
CORPORATE PRESENTATION NOVEMBER 2020
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains forward-looking statements within the meaning of the Israeli securities law that involve risks and uncertainties. These forward-looking statements relating to future events and future performance of the Company and the portfolio companies, jointly or separately
Slide 3: What to Look for in 2021
WHAT TO LOOK FDA Phase 1 FOR IN 2021 approval initiation stem cell transplant COVID-19 vaccine for hematologic malignancies 2 FDA marketing Phase 3 approvals Omidubicel results ELI-005 stem cells mobilization for multiple myeloma 3 advanced clinical trial readouts Phase 2 FDA interim data Motixafort
Slide 4: Clal Biotechnology Industries
CLAL BIOTECHNOLOGY INDUSTRIES Leading life sciences investment Team based in A member of Len Blavatnik’s Tel Aviv and Boston Shareholders company traded on the stock Access Industries group exchange (TASE: CBI) Access Industries Clal Industries CBI Public 22% Clal industries 47% Collaborations with
Slide 5: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Robert Connelly Strategic Advisor 5
Slide 6: Diverse Clinical Development Activity
DIVERSE CLINICAL DEVELOPMENT ACTIVITY Company Pre-Clinical Phase I Phase II Phase III Market MediWound 35% Severe burns/ chronic wounds (Nasdaq: MDWD) Gamida Cell 6% Cord blood stem cells for transplantation (Nasdaq: GMDA) Biokine 25% Marrow cells mobilization in cancer Cadent 13% CNS disorders eXIt
Slide 7: Balanced Portfolio
BALANCED POTFOLIO Stage of Development Asset Distribution Therapeutic Areas Public, 31% Phase I 10% CNS Preclinical 25% 35% Oncology 37% Med-Tech 38% Biopharma 62% Phase II Wound 35% care 13% Phase III COVID-19 20% Hematology 13% 12% Private, 69% 7 7
Slide 8: Portfolio Companies
PORTFOLIO COMPANIES
Slide 9: The World Leader in Cord Blood Stem Cell Therapy
THE WORLD LEADER IN CORD BLOOD STEM CELL THERAPY Phase III trial primary endpoint: cumulative incidence Unique technology for the expansion of cord blood-derived stem cells of neutrophil engraftment Omidubicel – treatment for hematological malignancies • Orphan drug status and ‘Breakthrough Therapy’
Slide 10: Revolutionizing Wound Care
REVOLUTIONIZING WOUND CARE Develops, manufactures & commercializes drugs for burns and wound care % Incidence of surgical eschar removal NexoBrid - an enzymatic orphan drug for burn debridement P<0.0001 • Marketed in the EU and other territories; becoming standard of care • Phase III trial for FDA a
Slide 11: Targeting Tumor Microenvironment to Fight Cancer
TARGETING TUMOR MICROENVIRONMENT TO FIGHT CANCER Small molecules and peptides disrupting cancer cell communications Motixafortide (BL-8040) - a novel high-affinity antagonist of CXCR4, mobilizing hematopoietic stem cells; orphan drug status in US and EU • Developed by BioLineRx (Nasdaq: BRLX) under
Slide 12: Novel Therapies for Neurological and Psychiatric Conditions
NOVEL THERAPIES FOR NEUROLOGICAL AND PSYCHIATRIC CONDITIONS Developing drugs for CNS disorders Positive or negative modulation of brain NMDA receptors: • MIJ821 - for treatment-resistant depression; licensing deal with Novartis provides for milestone payments of up to $386 million, plus royalties; a
Slide 13: Driving the Immune System to Eliminate Cancer
DRIVING THE IMMUNE SYSTEM TO ELIMINATE CANCER Developing potent next generation, lymph node-targeting, immuno- modulatory therapeutic and prophylactic vaccines for cancer and infectious diseases • Lymph node targeting aims to achieve potent immune activation, robust T cell response, immune memory, a
Slide 14: Thrombosis Prevention Avoiding Bleeding Risk
THROMBOSIS PREVENTION AVOIDING BLEEDING RISK Phase I trial coagulation data World leader in developing novel, safer, first-in-class antithrombotic drugs • Despite the benefits of available anticoagulants, all convey significant bleeding risk • Factor XI antagonists inhibit the intrinsic clotting pat
Slide 15: Med-Tech Portfolio
MED-TECH PORTFOLIO Sight Diagnostics Colospan Pi-Cardia MinInvasive FDNA Commercializing Developing CG-100, an Developing LeaflexTM, a Commercializing Deploying Face2Gene: OLOTM, a novel AI and anastomosis protection novel catheter for OmniCuffTM - a AI-based platform to optical, FDA approved, devic
Slide 16: Looking Ahead
LOOKING AHEAD
Slide 17: Upcoming Events - Value Creating Milestones
UPCOMING EVENTS - VALUE CREATING MILESTONES 2020 2021 Omidubicel Omidubicel GDA-201 Omidubicel Omidubicel Omidubicel Gamida Cell phase 3 top line results Financing phase1/2 readout phase 1 data phase 3 readout BLA submission FDA approval (hematological malignancies) $69M (aplastic anemia) (NHL) (hem
Slide 18: Ready to Materialize
READY TO MATERIALIZE Collaborations with multinational Advanced technologies from Diverse portfolio with healthcare companies and major the best institutions and minds in world class leadership investment funds Israel and US Mature portfolio of late-stage Drug candidates for significant Portfolio co
Slide 19: www.cbi.co.il
CLAL BIOTECHNOLOGY INDUSTRIES WWW.CBIL.CO.IL
Clal Biotechnology Industries — Investor Presentation (November 2020) on 6ix